嘉事堂(002462) - 2020 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was CNY 23,256,135,891.33, representing a 4.82% increase compared to CNY 22,186,572,874.61 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 317,585,422.67, a decrease of 15.53% from CNY 375,957,176.99 in 2019[16] - The net cash flow from operating activities increased significantly by 280.35% to CNY 1,114,869,517.58, compared to CNY 293,114,556.75 in 2019[16] - The total assets at the end of 2020 were CNY 14,133,717,238.25, an increase of 8.41% from CNY 13,037,391,923.99 at the end of 2019[17] - The net assets attributable to shareholders increased by 5.94% to CNY 3,628,935,746.35 from CNY 3,425,524,154.59 in 2019[17] - The basic earnings per share for 2020 was CNY 1.09, down 24.31% from CNY 1.44 in 2019[16] - The company reported a weighted average return on equity of 9.01%, down from 13.38% in 2019[16] - The quarterly operating revenue for Q4 2020 was CNY 6,967,574,934.06, showing a strong performance in the last quarter[20] Revenue Breakdown - Pharmaceutical wholesale revenue accounted for ¥22.64 billion, which is 97.34% of total revenue, showing a slight decrease of 0.72% compared to ¥21.76 billion in 2019[36] - Revenue from the Beijing region decreased by 4.84% to ¥8.55 billion, while revenue from other regions increased by 4.84% to ¥14.70 billion[36] - The gross profit margin for pharmaceutical wholesale was 8.77%, a decrease of 1.37% from the previous year[39] - Sales volume for pharmaceutical wholesale increased by 4.05% to ¥22.64 billion, while inventory decreased by 12.37% to ¥1.94 billion[41] Cash Flow and Investments - The company reported a 28% increase in cash and cash equivalents, attributed to timely collection of receivables[29] - The total cash inflow from operating activities was ¥25,427,615,623.77 in 2020, up 3.40% from ¥24,592,375,383.27 in 2019[48] - The net cash flow from financing activities decreased by 172.38% to -¥373,545,649.76 in 2020 from ¥516,115,013.34 in 2019[49] - The company's cash flow from investment activities saw a net outflow of -¥293,544,718.21 in 2020, a decrease of 7.89% from -¥318,698,984.95 in 2019[48] Dividend Distribution - The company plans to distribute a cash dividend of CNY 3.3 per 10 shares, totaling CNY 96,000,000 based on 291,707,120 shares[4] - The cash dividend for 2020 represented 30.31% of the net profit attributable to ordinary shareholders, while the 2019 and 2018 dividends were 31.04% and 11.47%, respectively[87] - The total cash dividend for 2020, including other methods, was 96,263,349.60 CNY, which accounted for 8.26% of the total profit distribution[88] Research and Development - R&D personnel increased to 146 in 2020 from 12 in 2019, a growth of 1,116.67%[47] - R&D investment rose to ¥23,565,800 in 2020 from ¥1,500,000 in 2019, an increase of 1,471.05%[47] - The proportion of R&D investment to operating revenue was 0.10% in 2020, up from 0.01% in 2019[47] Corporate Governance - The company maintains a strict governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[177] - The company has established a complete independent business system, with no reliance on related transactions for its main business income and profits[180] - All senior management personnel are appointed through legal procedures, ensuring independence from the controlling shareholder[181] Social Responsibility - The company reported a total of 370 million RMB invested in targeted poverty alleviation efforts in Hunan province[128] - Direct donations of 2.3 million RMB were made through the Everbright Trust account for poverty alleviation initiatives[128] - During the pandemic, the company donated nearly 200,000 RMB worth of anti-epidemic supplies to designated poverty alleviation counties[128] Subsidiaries and Market Position - The company established several new subsidiaries in 2020, including Shanghai Jiashiluexi Medical Equipment Co., Ltd. and Jiangsu Jiashijimei Medical Technology Co., Ltd.[42] - The company maintained its leading position in pharmaceutical distribution in Beijing while expanding its medical device and consumables services nationwide[26] Audit and Compliance - The audit report issued by Ernst & Young Huaming Certified Public Accountants provided a standard unqualified opinion on the financial statements for the year ended December 31, 2020[199] - There were no significant deficiencies identified in the internal control evaluation report for the reporting period[191] Employee Information - The total number of employees in the company is 3,031, with 2,780 in major subsidiaries and 251 in the parent company[170] - The total remuneration for directors and senior management during the reporting period amounts to 979.41 million yuan[170] - The company has 2,225 sales personnel, making up the largest segment of its workforce[170]